DE1445121A1 - 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen - Google Patents

2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen

Info

Publication number
DE1445121A1
DE1445121A1 DE19611445121 DE1445121A DE1445121A1 DE 1445121 A1 DE1445121 A1 DE 1445121A1 DE 19611445121 DE19611445121 DE 19611445121 DE 1445121 A DE1445121 A DE 1445121A DE 1445121 A1 DE1445121 A1 DE 1445121A1
Authority
DE
Germany
Prior art keywords
chloro
methyl
sulfamyl
dihydro
dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19611445121
Other languages
German (de)
English (en)
Inventor
Mclamore William Merrill
Mcmanus James Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE1445121A1 publication Critical patent/DE1445121A1/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/261,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/301,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04DNON-POSITIVE-DISPLACEMENT PUMPS
    • F04D29/00Details, component parts, or accessories
    • F04D29/08Sealings
    • F04D29/10Shaft sealings
    • F04D29/12Shaft sealings using sealing-rings
    • F04D29/126Shaft sealings using sealing-rings especially adapted for liquid pumps
    • F04D29/128Shaft sealings using sealing-rings especially adapted for liquid pumps with special means for adducting cooling or sealing fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mechanical Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Structures Of Non-Positive Displacement Pumps (AREA)
DE19611445121 1960-09-27 1961-06-24 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen Pending DE1445121A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58632A US3102882A (en) 1960-09-27 1960-09-27 Derivatives of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide
GB991/61A GB902658A (en) 1960-09-27 1961-01-10 6-substituted (or unsubstituted) 2-alkyl-3-allylthiomethyl-7-sulphamyl-3,4-dihydrobenzothiadiazine dioxides and process for preparation

Publications (1)

Publication Number Publication Date
DE1445121A1 true DE1445121A1 (de) 1968-11-28

Family

ID=26236340

Family Applications (2)

Application Number Title Priority Date Filing Date
DENDAT1302648D Pending DE1302648B (US07368562-20080506-C00013.png) 1960-09-27
DE19611445121 Pending DE1445121A1 (de) 1960-09-27 1961-06-24 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DENDAT1302648D Pending DE1302648B (US07368562-20080506-C00013.png) 1960-09-27

Country Status (6)

Country Link
US (1) US3102882A (US07368562-20080506-C00013.png)
BE (1) BE606063A (US07368562-20080506-C00013.png)
DE (2) DE1445121A1 (US07368562-20080506-C00013.png)
ES (1) ES270748A1 (US07368562-20080506-C00013.png)
FR (1) FR1426M (US07368562-20080506-C00013.png)
GB (2) GB902658A (US07368562-20080506-C00013.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US3251837A (en) * 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US4338435A (en) * 1981-06-01 1982-07-06 E. R. Squibb & Sons, Inc. Benzothiadiazines having diuretic activity
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
US3102882A (en) 1963-09-03
GB902658A (en) 1962-08-09
DE1302648B (US07368562-20080506-C00013.png)
ES270748A1 (es) 1961-12-16
FR1426M (fr) 1962-08-06
GB905137A (en) 1962-09-05
BE606063A (fr) 1962-01-12

Similar Documents

Publication Publication Date Title
DE1445121A1 (de) 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen
DE2238628A1 (de) Verfahren zur herstellung von furanverbindungen
DE1470029C3 (de) Verfahren zur Herstellung von Thiaxanthenderivaten
DE2461604A1 (de) 8-hydroxy-3,4-dihydrocarbostyril- derivate, verfahren zu ihrer herstellung und arzneimittel
DE2340873A1 (de) Morpholinderivate
EP0008645A1 (de) Alkoxyphenylpyrrolidone, Verfahren zu ihrer Herstellung und Arzneimittel auf Basis dieser Verbindungen
DE1518452C3 (de) 4 substituierte 2 Benzhydryl 2 butanol Derivate und Verfahren zu ihrer Herstellung
DE1212090B (de) Verfahren zur Herstellung von 10-(Piperazinopropyl)-3-trifluormethyl-phenothiazinverbindungen und ihren Salzen
DE2627223C2 (US07368562-20080506-C00013.png)
CH616416A5 (US07368562-20080506-C00013.png)
DE2534962B2 (de) cis-3,4-Ureylenthiophan-l,1-dioxid und Verfahren zu seiner Herstellung
DE2406972C3 (de) Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2131330A1 (de) Imidazo-[1,2-a]-benzimidazolderivate und Verfahren zur Herstellung derselben
DE1420041A1 (de) Verfahren zur Herstellung von basisch alkylierten Acylpheonthiazinen
DE1122070C2 (de) Verfahren zur Herstellung von diuretisch wirksamen Disulfamylanilinverbindungen
AT244344B (de) Verfahren zur Herstellung von neuen Pyrimidinverbindungen
AT204046B (de) Verfahren zur Herstellung von neuen Piperazinderivaten und von deren Salzen
AT226732B (de) Verfahren zur Herstellung von neuen Guanidinverbindungen
AT223195B (de) Verfahren zur Herstellung von neuen 3,4-Dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
DE2306001C3 (de) Pyrimidinderivate, Verfahren zu deren Herstellung und diese enthaltende Geflügelfutterzusammensetzungen
CH451961A (de) Verfahren zur Herstellung von Hydroxamsäureestern
DE825409C (de) Verfahren zur Herstellung von Chinoliniumverbindungen
CH506544A (de) Verfahren zur Herstellung von biologisch aktiven substituierten s-Triazinen
DE1493994A1 (de) Verfahren zur Herstellung von Phenoxyessigsaeureverbindungen
AT231445B (de) Verfahren zur Herstellung von neuen 1, 2, 4-Triazolonen-(5)